KAI is a clinical-stage, biopharmaceutical company whose lead peptide product candidate, KAI-4169, is in development for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). CKD-MBD is characterized by an elevation of parathyroid hormone also referred to as secondary hyperparathyroidism. (SHPT). Building on promising, early-stage clinical data, KAI has advanced KAI-4169 into Phase 2 clinical development in end-stage renal disease (ESRD) patients on dialysis, which is expected to complete in the second half of 2011. In addition, preclinical research is being conducted on pre-hemodialysis applications of KAI-4169. KAI’s leadership team has a strong background and track record in successful product development and commercialization. The Company is backed by a leading syndicate of venture investors, having raised a combined total of $63 million in Series A and B rounds. KAI is headquartered in South San Francisco, California.